Who do I have to suck for some eloralintide

[TopzyTirzy]

I don’t have any experience, but I have a great attitude and really want some eloralintide. I could really make some chinese peptide manufacturers weekend nice if given the chance.
Sema and tirz both give me anhedonia, and this chest anxiety/tachycardia, reta doesnt, but i want more appetite suppressant. Just ordered cagri, but I want the new fancy amylin receptor agonist😭, I also think it has a heart rate lowering effect which would be nice.

Why do these random biotech phds in china take so long in getting me illicit cutting edge pharmaceuticals when IIIII WANTTTT THEM NOW

 

[miss-sanne]

Why don’t you just use the cagri you ordered ? I love it, 0,25 mg is so good.
Eloralintide is not even in phase 1 trial yet ?
Why would you choose that ?

 

[KYRivianMan]

I don’t have any experience, but I have a great attitude and really want some eloralintide. I could really make some chinese peptide manufacturers weekend nice if given the chance.
Sema and tirz both give me anhedonia, and this chest anxiety/tachycardia, reta doesnt, but i want more appetite suppressant. Just ordered cagri, but I want the new fancy amylin receptor agonist😭, I also think it has a heart rate lowering effect which would be nice.

Why do these random biotech phds in china take so long in getting me illicit cutting edge pharmaceuticals when IIIII WANTTTT THEM NOW

Really? Have to suck?

 

[IshimaruKenta]

Really? Have to suck?

I think the proper term is "want to suck".

 

[m100568]

Eloralintide is not even in phase 1 trial yet ?

Actually, the Phase II results were released during Obesity Week. That was the cause for the excitement. Phase III is supposed to start before the end of 2025. Reta has been a grey market staple since it released its Phase II data, so I don't see why the grey market wouldn't produce it based on such good Phase II results.
----------------------------------------------------------------------------------------------

Eloralintide Phase II results​

According to the study authors, 263 participants (mean age 49.0 years, mean bodyweight 109.1 kg, BMI 39.1 kg/m², 78% female, 78% White) were randomized to receive either eloralintide (1 mg, n=28; 3 mg, n=24; 6 mg, n=28; 9 mg, n=54; 6-9 mg, n=24; 3-9 mg, n=52) or placebo (n=53) between Feb. 5, 2024, and Aug. 14, 2025.2

Emerging data from the Phase II trial show:

• After 48 weeks, mean percent change in bodyweight from baseline (efficacy estimand) ranged from -9% at 1 mg to -20% at 9 mg, compared with -0.4% in the placebo group.
• The greatest weight reductions were observed in the 9 mg and 6-9 mg cohorts (-20% each; 95% CI: -22.7 to -17.5 and -22.7 to -17.0, respectively).

“Eloralintide produced clinically meaningful, dose-dependent reductions in bodyweight over 48 weeks and was generally well tolerated, supporting eloralintide's potential use for obesity treatment,” the authors wrote.

 

[IshimaruKenta]

They're also testing it dosed with tirzepatide. Not sure if they have a pH requirement like cagrilintide, so it'll be interesting to see how that plays out.

 

[YoYoFat]

Yeah, I’m surprised we’re not seeing it from vendors already. That recipe must be under lock and key, or too expensive to reproduce.

 

[IshimaruKenta]

Yeah, I’m surprised we’re not seeing it from vendors already. That recipe must be under lock and key, or too expensive to reproduce.

The sequence was just published, so hopefully soon?

 

[m100568]

Yeah, I’m surprised we’re not seeing it from vendors already. That recipe must be under lock and key, or too expensive to reproduce.

I think they just published the details of the sequence. From what I read it isn't that complicated (not that I am a peptide production expert).

 

[m100568]

Ok, sent the sequence to Chatgpt. I won't bore everyone with the pages of details, but here is the conclusion:
----------------------------------------------------------------------------------------------------

🧪 Where eloralintide sits in difficulty relative to tirzepatide & retatrutide​

Feature	Tirzepatide	Retatrutide	Eloralintide	Difficulty
Length	~39 aa	~40 aa	~40 aa	Same
Lipid tail	γGlu–γGlu–C20	γGlu–γGlu–C20	γGlu–γGlu–C20	Same
Cys handling	None	None	Two Cys w/ thioether bridge	Eloralintide harder
Non-standard residues	Yes	Yes	Yes	Same
GMP / large scale	Yes	Yes	Depends on vendor	Vendor-specific

Conclusion:
The only added complexity is the thioether bridge. Everything else is squarely in the wheelhouse of a tirzepatide vendor.

 

[miss-sanne]

Actually, the Phase II results were released during Obesity Week. That was the cause for the excitement. Phase III is supposed to start before the end of 2025. Reta has been a grey market staple since it released its Phase II data, so I don't see why the grey market wouldn't produce it based on such good Phase II results.
----------------------------------------------------------------------------------------------

Eloralintide Phase II results​

According to the study authors, 263 participants (mean age 49.0 years, mean bodyweight 109.1 kg, BMI 39.1 kg/m², 78% female, 78% White) were randomized to receive either eloralintide (1 mg, n=28; 3 mg, n=24; 6 mg, n=28; 9 mg, n=54; 6-9 mg, n=24; 3-9 mg, n=52) or placebo (n=53) between Feb. 5, 2024, and Aug. 14, 2025.2

Emerging data from the Phase II trial show:

• After 48 weeks, mean percent change in bodyweight from baseline (efficacy estimand) ranged from -9% at 1 mg to -20% at 9 mg, compared with -0.4% in the placebo group.
• The greatest weight reductions were observed in the 9 mg and 6-9 mg cohorts (-20% each; 95% CI: -22.7 to -17.5 and -22.7 to -17.0, respectively).

“Eloralintide produced clinically meaningful, dose-dependent reductions in bodyweight over 48 weeks and was generally well tolerated, supporting eloralintide's potential use for obesity treatment,” the authors wrote.

thanks, didn't know !

 

[YoYoFat]

Ok, sent the sequence to Chatgpt. I won't bore everyone with the pages of details, but here is the conclusion:
----------------------------------------------------------------------------------------------------

🧪 Where eloralintide sits in difficulty relative to tirzepatide & retatrutide​

Feature	Tirzepatide	Retatrutide	Eloralintide	Difficulty
Length	~39 aa	~40 aa	~40 aa	Same
Lipid tail	γGlu–γGlu–C20	γGlu–γGlu–C20	γGlu–γGlu–C20	Same
Cys handling	None	None	Two Cys w/ thioether bridge	Eloralintide harder
Non-standard residues	Yes	Yes	Yes	Same
GMP / large scale	Yes	Yes	Depends on vendor	Vendor-specific

Conclusion:
The only added complexity is the thioether bridge. Everything else is squarely in the wheelhouse of a tirzepatide vendor.

What’s “cys handling”?

 

[miss-sanne]

What’s “cys handling”?

isn't it some chemical stuff, a konfiguration, - the peptides 'blueprint' ?
Because of the konfiguration, it's more difficult to make ?
Cys may be 'cystein', the amino acid ??
I'm not a chemist, though ;-)

 

[Calm Logic]

Sema and tirz both give me anhedonia, and this chest anxiety/tachycardia, reta doesnt, but i want more appetite suppressant. Just ordered cagri, but I want the new fancy amylin receptor agonist😭, I also think it has a heart rate lowering effect which would be nice.

Why do these random biotech phds in china take so long in getting me illicit cutting edge pharmaceuticals when IIIII WANTTTT THEM NOW

What dose of reta are you on? I always wait until I'm at the maximum dose of a GLP before offering services.

 

[keangkong]

Why don’t you just use the cagri you ordered ? I love it, 0,25 mg is so good.
Eloralintide is not even in phase 1 trial yet ?
Why would you choose that ?

Eloranlintide has completed at least one phase 2 trial. Billings, et al. (pre-publication, 2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity - a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet, doi-10.1016/S0140-6736(25)02155-5. At least one other phase two trial is ongoing. Hsia, et al (Obesity Week 2025). Poster - Eloralintide Phase 2 Study in Adult Participants With Overweight or Obesity - Design and Study Population. Yes, elorantlintide is behnd reta in development and far behind tirz. Still much work has been done on developing it.

 

[miss-sanne]

Eloranlintide has completed at least one phase 2 trial. Billings, et al. (pre-publication, 2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity - a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet, doi-10.1016/S0140-6736(25)02155-5. At least one other phase two trial is ongoing. Hsia, et al (Obesity Week 2025). Poster - Eloralintide Phase 2 Study in Adult Participants With Overweight or Obesity - Design and Study Population. Yes, elorantlintide is behnd reta in development and far behind tirz. Still much work has been done on developing it.

Thanks yes I realized that now, thanks for this !
It seems, it’s much more weight loss than cagri. (Why the pairing of sema and cagri).

 

[Dogmandu]

Ok, sent the sequence to Chatgpt. I won't bore everyone with the pages of details, but here is the conclusion:
----------------------------------------------------------------------------------------------------

🧪 Where eloralintide sits in difficulty relative to tirzepatide & retatrutide​

Feature	Tirzepatide	Retatrutide	Eloralintide	Difficulty
Length	~39 aa	~40 aa	~40 aa	Same
Lipid tail	γGlu–γGlu–C20	γGlu–γGlu–C20	γGlu–γGlu–C20	Same
Cys handling	None	None	Two Cys w/ thioether bridge	Eloralintide harder
Non-standard residues	Yes	Yes	Yes	Same
GMP / large scale	Yes	Yes	Depends on vendor	Vendor-specific

Conclusion:
The only added complexity is the thioether bridge. Everything else is squarely in the wheelhouse of a tirzepatide vendor.

Given how China has run away with Eli Lilly's IP on Tirz and Reta, EL's patent attorneys will have thought long and hard on how to disclose Elora details to the patent office. You cannot legally withhold technical details in a patent app. However, you can strategically craft your disclosure so that others cannot easily reproduce the peptide. They didn't do that with Tirz (fool me once) and again not with Reta (fool me twice) and so what is our collective guess as to what they will do with Elora?

They can do this by claiming families of sequences. Example: position X contains a noncanonical α-methyl-Leu. Another way is to incorporate a key manufacturing that they never have to disclose. Example: resin chemistry or buffer conditions. Another tactic is to disclose one workable embodiment (recipe) but not the good one that works.

I used to be a chemist in the beverage industry and own one chemistry patent. I've worked with patent attorneys. So this is all an educated guess. More like a worry.

Our Chinese grey friends may be real busy splish-splashing Elora in their bathtubs, but what the heck are they making? May be Elora spot on. May be something close. When the first grey Elora shipment drops, my thinking will be 'You first!'